A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Latest Information Update: 13 Dec 2021
At a glance
- Drugs Riociguat (Primary)
- Indications Diffuse scleroderma
- Focus Therapeutic Use
- Acronyms RISE-SSc
- Sponsors Bayer
- 15 Jul 2020 Results published in the Annals of the Rheumatic Diseases
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 06 Jun 2020 Results of open-label long-term extension (LTE) of RISE-SSc presented at the 21st Annual Congress of the European League Against Rheumatism